公开(公告)号：US20200231564A9

公开(公告)日：2020-07-23

申请号：US16286700

申请日：2019-02-27

申请人： Trevena, Inc.

发明人： Aimee Crombie Speerschneider ,  Dennis Shinji Yamashita ,  Philip Michael Pitis ,  Michael John Hawkins ,  Guodong Liu ,  Tamara Ann Miskowski Daubert ,  Catherine C.K. Yuan ,  Robert Borbo Kargbo ,  Robert Jason Herr ,  Donna Romero ,  Gregory J. Pacofsky

IPC分类号： C07D401/12 ,  C07D405/14 ,  C07D403/12 ,  C07D451/02 ,  A61K31/445 ,  C07D241/04 ,  C07D211/22 ,  C07D401/14

摘要： The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.

公开(公告)号：US20200087239A1

公开(公告)日：2020-03-19

申请号：US16685335

申请日：2019-11-15

申请人： GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

发明人： Ivan William HEMEON ,  Brian Salvatore SAFINA ,  Daniel SUTHERLIN

IPC分类号： C07C62/38 ,  C07C69/757 ,  C07C62/34 ,  C07C229/48 ,  C07D211/22 ,  C07C317/44 ,  C07C323/61 ,  A61P25/00 ,  A61P29/00 ,  A61P17/04 ,  C07C313/04

摘要： The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20200080086A1

公开(公告)日：2020-03-12

申请号：US16692284

申请日：2019-11-22

申请人： DAIICHI SANKYO COMPANY, LIMITED

发明人： Makoto KOIZUMI ,  Yoshiyuki ONISHI ,  Takako NIWA ,  Masakazu TAMURA ,  Yuji KASUYA

IPC分类号： C12N15/113 ,  A61K48/00 ,  A61K47/44 ,  A61K47/28 ,  A61K47/22 ,  A61K47/18 ,  A61K9/127 ,  A61K9/10 ,  A61K47/54 ,  C12N15/11 ,  C07D211/46 ,  C07D211/22 ,  C07C219/16 ,  A61K31/713 ,  A61K31/7088

摘要： The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

公开(公告)号：US20200050105A1

公开(公告)日：2020-02-13

申请号：US16530438

申请日：2019-08-02

申请人： Shin-Etsu Chemical Co., Ltd.

发明人： Jun Hatakeyama ,  Masaki Ohashi ,  Takayuki Fujiwara

IPC分类号： G03F7/004 ,  G03F7/039 ,  G03F7/038 ,  C07D295/088 ,  C07C217/06 ,  C07D235/12 ,  C07D211/22 ,  C07D207/08 ,  C07D211/46 ,  C07D453/02 ,  C07D209/52 ,  C07D451/02

摘要： A resist composition comprising a base polymer and a quencher in the form of an amine compound having an iodized aromatic ring bonded to the nitrogen atom via a divalent hydrocarbon group offers a high sensitivity and minimal LWR or improved CDU, independent of whether it is of positive or negative tone.

公开(公告)号：US20200000792A1

公开(公告)日：2020-01-02

申请号：US16559928

申请日：2019-09-04

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Lori Jean Patterson ,  Eric L. Stangeland

IPC分类号： A61K31/4465 ,  C07D211/22 ,  C07D211/32

摘要： The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

公开(公告)号：US10329255B2

公开(公告)日：2019-06-25

申请号：US15234053

申请日：2016-08-11

申请人： Incyte Corporation

发明人： Yongchun Pan ,  Wayne Han ,  Ganfeng Cao ,  Zhongjiang Jia ,  Vaqar Sharief ,  Jiacheng Zhou

IPC分类号： C07D211/22 ,  C07D211/26 ,  C07D211/32

摘要： The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.

公开(公告)号：US20190142816A1

公开(公告)日：2019-05-16

申请号：US16244956

申请日：2019-01-10

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Lori Jean Patterson ,  Robert S. Chao ,  Miroslav Rapta

IPC分类号： A61K31/4465 ,  C07D211/22 ,  C07D211/32

摘要： The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.

公开(公告)号：US20190134019A1

公开(公告)日：2019-05-09

申请号：US16239265

申请日：2019-01-03

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Lori Jean Patterson ,  Eric L. Stangeland

IPC分类号： A61K31/4465 ,  C07D211/22 ,  C07D211/32

CPC分类号： A61K31/4465 ,  C07D211/22 ,  C07D211/32

摘要： The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

公开(公告)号：US20180290965A1

公开(公告)日：2018-10-11

申请号：US16013048

申请日：2018-06-20

申请人： Novartis AG

发明人： Luis Brito ,  Delai Chen ,  Gabriel Grant Gamber ,  Andrew Geall ,  Kevin Love ,  Thomas Zabawa ,  Frederic Zecri

IPC分类号： C07C229/12 ,  C07D211/44 ,  A61K39/39 ,  C07C271/22 ,  C07D211/06 ,  A61K31/713 ,  A61K31/7105 ,  A61K9/51 ,  A61K9/127 ,  A61K47/18 ,  C07C219/04 ,  C07C271/20 ,  C07D295/15 ,  C07D211/62 ,  C07D211/60 ,  C07D211/46 ,  C07D295/088 ,  C07D211/22 ,  C07D207/16 ,  C07D207/12 ,  C07D265/30 ,  C07D205/04 ,  C07C229/38 ,  C07D211/34

摘要： This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L1, n and p are defined herein. The compounds of formula (X) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

公开(公告)号：US20180289687A1

公开(公告)日：2018-10-11

申请号：US16007233

申请日：2018-06-13

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Lori Jean Patterson ,  Eric L. Stangeland

IPC分类号： A61K31/4465 ,  C07D211/22 ,  C07D211/32

CPC分类号： A61K31/4465 ,  C07D211/22 ,  C07D211/32

摘要： The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.